Obesity Increases Prostate Cancer Risk After Negative Biopsy

This article originally appeared here.
Share this content:

HealthDay News -- In men with an initial benign biopsy or transurethral resection of the prostate, obesity at the time of the procedure is associated with the presence of precancerous lesions in the initial biopsy and a higher risk of developing prostate cancer, according to a study published online April 23 in Cancer Epidemiology, Biomarkers & Prevention.

Andrew Rundle, DrPH, from Columbia University in New York City, and colleagues examined the association of obesity with future prostate cancer risk in 494 men who had undergone benign biopsy or transurethral resection of the prostate and 494 matched controls.

The researchers found that prostatic intraepithelial neoplasia (PIN) was present in 11% of the initial benign biopsies. Obesity at the time of the initial procedure was associated with a higher likelihood of PIN in the initial biopsy (odds ratio, 2.15) and with a higher incidence of prostate cancer during follow-up, after adjusting for a number of variables (odds ratio, 1.57). The higher prostate cancer risk was only found in cases diagnosed earlier, with less than 1,538 days of follow-up.

"Obesity is associated with the presence of PIN in benign specimens and with future prostate cancer risk after an initial benign finding," Rundle and colleagues conclude.

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs